Evidence map›Paper›PMID 26329396›Full record

Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2016

Buspirone for management of dyspnea in cancer patients receiving chemotherapy: a randomized placebo-controlled URCC CCOP study.

Anita R Peoples, Peter W Bushunow, Sheila N Garland, Charles E Heckler, Joseph A Roscoe, Luke L Peppone, Deborah J Dudgeon, Jeffrey J Kirshner, Tarit K Banerjee, Judith O Hopkins and 3 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 2 countries.

Anita R PeoplesUniversity of Rochester Cancer Center Community Clinical Oncology Program Research Base, Behavioral Medicine Unit, University of Rochester Medical Center, 265 Crittenden Blvd., CU 420658, Rochester, NY, 14642, USA. anita_peoples@urmc.rochester.edu.ORCID http://orcid.org/0000-0003-3645-3960
Peter W BushunowLipson Cancer Center, Rochester General Hospital, 1425 Portland Avenue, Rochester, NY, 14621, USA.
Sheila N GarlandDepartment of Family Medicine and Community Health, University of Pennsylvania, Philadelphia, PA, USA.
Charles E HecklerUniversity of Rochester Cancer Center Community Clinical Oncology Program Research Base, Behavioral Medicine Unit, University of Rochester Medical Center, 265 Crittenden Blvd., CU 420658, Rochester, NY, 14642, USA.
Joseph A RoscoeUniversity of Rochester Cancer Center Community Clinical Oncology Program Research Base, Behavioral Medicine Unit, University of Rochester Medical Center, 265 Crittenden Blvd., CU 420658, Rochester, NY, 14642, USA.
Luke L PepponeUniversity of Rochester Cancer Center Community Clinical Oncology Program Research Base, Behavioral Medicine Unit, University of Rochester Medical Center, 265 Crittenden Blvd., CU 420658, Rochester, NY, 14642, USA.
Deborah J DudgeonPalliative Care Medicine, Department of Internal Medicine, Queen's University, Kingston, ON, Canada.
Jeffrey J KirshnerHOACNY CCOP, 5008 Brittonfield Parkway, Suite #700, PO Box 2050, East Syracuse, NY, 13057, USA.
Tarit K BanerjeeMarshfield CCOP, Marshfield Clinic, 1000 N. Oak Avenue, 2R-1 Lawton Center, Marshfield, WI, 54449, USA.
Judith O HopkinsSoutheast Cancer Control consortium, 2150 Country Club Road, Suite 200, Winston-Salem, NC, 27104, USA.
Shaker R DakhilWichita CCOP, 929 North St. Frances, Wichita, KS, 67214, USA.
Marie A FlanneryUniversity of Rochester Cancer Center Community Clinical Oncology Program Research Base, Behavioral Medicine Unit, University of Rochester Medical Center, 265 Crittenden Blvd., CU 420658, Rochester, NY, 14642, USA.
Gary R MorrowUniversity of Rochester Cancer Center Community Clinical Oncology Program Research Base, Behavioral Medicine Unit, University of Rochester Medical Center, 265 Crittenden Blvd., CU 420658, Rochester, NY, 14642, USA.
University of Rochester Medical Center · USHematology Oncology Associates of Central New York · USMarshfield Clinic · USQueen's University · CARochester General Hospital · USSoutheast Clinical Oncology Research Consortium · USUniversity of Pennsylvania Health System · USWichita Clinic · US

Funding

URCC NCORP Research BaseUG1CA189961 · NCI · UNIVERSITY OF ROCHESTER · PI Michelle C Janelsins, KAREN M. MUSTIAN · 2014 to 2026
$67.7M
UNIVERSITY OF ROCHESTER--CCOP RESEARCH BASEU10CA037420 · NCI · UNIVERSITY OF ROCHESTER · PI MORROW, GARY R · 1985 to 2014
$21.1M
Cancer Control Research Training Curriculum (R25T)R25CA102618 · NCI · UNIVERSITY OF ROCHESTER · PI JANELSINS, MICHELLE C, MORROW, GARY R · 2004 to 2018
$6.7M
Management of Cancer-Treatment-Induced Bone LossK07CA168911 · NCI · UNIVERSITY OF ROCHESTER · PI PEPPONE, LUKE JOSEPH · 2013 to 2017
$724k
NCI NIH HHS K07 CA168911NCI NIH HHS R25 CA102618NCI NIH HHS R25CA10618NCI NIH HHS U10 CA037420NCI NIH HHS U10 CA37420NCI NIH HHS UG1 CA189961
6 · The paper itself

Abstract

purposeCancer-related dyspnea is a common, distressing, and difficult-to-manage symptom in cancer patients, resulting in diminished quality of life and poor prognosis. Buspirone, a non-benzodiazepine anxiolytic which does not suppress respiration and has proven efficacy in the treatment of generalized anxiety disorder, has been suggested to relieve the sensation of dyspnea in patients with COPD. The main objective of our study was to evaluate whether buspirone alleviates dyspnea in cancer patients.

methodsWe report on a randomized, placebo-controlled trial of 432 patients (mean age 64, female 51%, lung cancer 62%) from 16 participating Community Clinical Oncology Program (CCOP) sites with grade 2 or higher dyspnea, as assessed by the Modified Medical Research Council Dyspnea Scale. Dyspnea was assessed by the Oxygen Cost Diagram (OCD; higher scores are better) and anxiety by the state subscale of the State-Trait Anxiety Inventory (STAI-S; lower scores are better) at baseline and after the 4-week intervention (post-intervention).

resultsMean scores from baseline to post-intervention for buspirone were OCD 8.7 to 9.0 and STAI-S 40.5 to 40.1 and for placebo were OCD 8.4 to 9.3 and STAI-S 40.9 to 38.6 with raw improvements over time on both measures being greater in the placebo group. Analysis of covariance (ANCOVA) controlling for baseline scores showed no statistically significant difference between groups for OCD (P = 0.052) or STAI-S (P = 0.062).

conclusionBuspirone did not result in significant improvement in dyspnea or anxiety in cancer patients. Thus, buspirone should not be recommended as a pharmacological option for dyspnea in cancer patients.

Indexed as

Anti-Anxiety AgentsAnxietyAnxiety DisordersBuspironeDisease ManagementDouble-Blind MethodDyspneaFemaleHumansMaleMiddle AgedNeoplasmsQuality of LifeAnti-Anxiety AgentsBuspironeAnxietyBuspironeCancerDyspnea

Identifiers

PMID26329396
PMCPMC4731275
OpenAlexW1246749579

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.